Experimental Radionuclide Therapy of HER2-Expressing Xenografts Using Two-Step Targeting Nuclisome Particles
暂无分享,去创建一个
[1] John W. Park,et al. In vitro evaluation and biodistribution of HER2-targeted liposomes loaded with an 125I-labelled DNA-intercalator , 2011, Journal of drug targeting.
[2] G. Scambia,et al. Pegylated liposomal doxorubicin in the management of ovarian cancer , 2010, Therapeutics and clinical risk management.
[3] R. Reilly,et al. Methotrexate, Paclitaxel, and Doxorubicin Radiosensitize HER2-Amplified Human Breast Cancer Cells to the Auger Electron–Emitting Radiotherapeutic Agent 111In-NLS-Trastuzumab , 2010, Journal of Nuclear Medicine.
[4] C. Bascoul-Mollevi,et al. Author manuscript, published in "Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2009;50 (12):2033-41" , 2010 .
[5] K. Edwards,et al. Nuclisome: a novel concept for radionuclide therapy using targeting liposomes , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[6] G. Adams,et al. Targeted Radionuclide Tumor Therapy , 2008 .
[7] H. Lundqvist,et al. The Auger effect in molecular targeting therapy. , 2008 .
[8] R. Reilly,et al. 111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer , 2007, Journal of Nuclear Medicine.
[9] H. Lundqvist,et al. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. , 2007, Cancer research.
[10] Chiara Brignole,et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. , 2006, Cancer research.
[11] K. Edwards,et al. A novel 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy. , 2006, Nuclear medicine and biology.
[12] U. Nielsen,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.
[13] Paul Chen,et al. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] C. Mamot,et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. , 2005, Cancer research.
[15] S. Schulz,et al. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] V. Tolmachev,et al. Synthesis and radioiodination of some daunorubicin and doxorubicin derivatives. , 2005, Carbohydrate research.
[17] A. Kassis. The Amazing World of Auger Electrons , 2004, International journal of radiation biology.
[18] T. Allen,et al. Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. , 2003, Cancer letters.
[19] Ulrik B Nielsen,et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. , 2002, Biochimica et biophysica acta.
[20] M. Waring,et al. Preferential binding of daunomycin to 5'ATCG and 5'ATGC sequences revealed by footprinting titration experiments. , 1990, Biochemistry.
[21] W. Prensky,et al. Death and metastatic distribution of tumor cells in mice monitored with 125I-iododeoxy-uridine. , 1969, Journal of the National Cancer Institute.